To overcome resistance to radiotherapy and chemotherapy in LC-CD133+, treatment of Oct-4 siRNA was used and results showed that the knockdown Oct-4 in LC-CD133+ can significantly improve the anti-cancer effect in single- or combination-treated LC-CD133+in vitro and in vivo (Figs. 6 and 7). The gene discussed is PROM1; the disease is laryngotracheoesophageal cleft.